Drug-Coated Balloons Market Trend, Share, Growth, Size and Forecast 2030

Industry Perspective:

The global drug-coated balloons market size was worth around USD 782.4 million in 2021 and is estimated to grow to about USD 1,819.2 million by 2028, with a compound annual growth rate (CAGR) of approximately 15.1% over the forecast period. The report analyzes the drug-coated balloons market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the drug-coated balloons market.

Request Free Sample

Drug-Coated Balloons Market: Overview

Drug-coating balloons are semi-compliant angioplasty balloons with anti-proliferative drugs coated on one or both sides. After balloon inflation, which is normally done at low pressures, the balloons are disseminated in the blood vessel walls. These balloons eliminate the need for repeated vascularization and significantly reduce cellularity. During the forecast period, it is anticipated that factors such as the high prevalence of cardiovascular diseases among the geriatric population as a result of contaminated food, booming research & development in the treatment of cardiovascular diseases, and an advanced healthcare infrastructure will propel the growth of the global drug-coated balloons market. Additionally, the market for drug-coated balloons is anticipated to grow due to rising government initiatives, increased research & development, and raising public awareness of cardiac ailments. The global market for drug-coated balloons is expected to expand gradually, nonetheless, due to the high cost of procedures and materials, as well as the stringent regulatory restrictions.

Request Free Sample

COVID-19 Impact:

The COVID-19 crisis has overburdened public health systems in a number of countries and highlighted the urgent requirement for long-term investments in healthcare infrastructure. As the COVID-19 pandemic spreads, the healthcare sector's growth is projected to stall. In several nations around the world, the COVID-19 pandemic is predicted to have a significant impact on the market for drug-coated balloons. Numerous hospitals, CATH labs, and ASCs have seen a sharp drop in elective cardiology procedures due to the pandemic. Even though COVID-19 is a worldwide pandemic, the virus has been more common in some nations than others.

Key Insights

• The global drug-coated balloons market value is expected to grow at a CAGR of 15.1% over the forecast period.
• In terms of revenue, the global drug-coated balloons market size was valued at USD 782.4 million in 2021 and is estimated to grow to about USD 1,819.2 million by 2028.
• Growing product advancements, an aging population, and an increase in vascular disease rates all contribute to the rise of the drug-coated balloon in the healthcare market.
• The region of North America dominated the market for drug-coated balloons in 2021.
• By indication, peripheral artery disease (PAD) accounted for more than 81% of the market in 2021 and is anticipated to continue dominating the segment during forecast period.
• By drug type, paclitaxel devices have the largest market share since they are both safe and effective in treating CVDs, AV, and urological issues.

Drug-Coated Balloons Market: Growth Drivers

Growing uses of drug-coated balloons in healthcare is predicted to fuel market growth

Drug-coated balloons are a new technique that has made it possible to treat many chronic ailments, including peripheral vascular disorders and cardiovascular conditions. Through cutting-edge goods and technologies, advances in medical procedures have made the treatment of blood vessel blockages easier. The market for drug-coated balloons is largely driven by the increasing prevalence of vascular disorders like heart, peripheral, and neurovascular, among others. For instance, the prevalence of cardiovascular diseases is rapidly increasing. Numerous variables, including obesity, a decline in physical activity, elevated stress levels, and a lifestyle change, have contributed to the rising prevalence of cardiovascular diseases. Such incidences are predicted to continue rising over the course of the forecast period, thus, encouraging growth of the global drug-coated balloons market.

Drug-Coated Balloons Market: Restraints

Growing alternatives to the use of drug-coated balloons will hamper the growth of the market

When compared to surgical treatment, which is frequently more expensive, percutaneous therapy is commonly preferred. For instance, a straightforward femoropopliteal bypass operation results in hospital and doctor fees of about USD 20,000. In addition, the cost would be significantly higher if there were any postoperative complications, such as infection. This factor will hamper the global drug-coated balloons market's growth due to the availability of lower-cost alternatives.

Drug-Coated Balloons Market: Opportunities

Rising government and private sector initiatives drives new opportunities for the market

As technology developed and healthcare research blossomed during the past ten years, the healthcare infrastructure underwent substantial changes. Through various initiatives, several governmental and commercial factors are making significant efforts to lower the prevalence of cardiovascular diseases. Governments and medical professionals have started educating the general public about PAD in industrialized countries. In September, the US marks "PAD Awareness Month." During this, medical device companies, physicians, payers, and healthcare professionals all participate. They try to educate individuals about the adverse effects of PAD and how to manage it during the awareness campaign. In addition, research teams are receiving money from several government organizations to assist them in creating drug-coated balloons that are more effective at treating cardiovascular diseases. This is projected to increase demand for drug-coated balloons worldwide in the upcoming years.

Drug-Coated Balloons Market: Segmentation

The global drug-coated balloons market is segregated on the basis of indication, drug type, end-user, and region. 

Based on indication, the market is divided into peripheral artery disease (PAD), coronary artery disease (CAD), and others. Peripheral artery disease (PAD) made up more than 81% of the market in 2021, and it is anticipated that it will continue to dominate the segment over the forecast period. Rapid growth in the use of drug-coated balloons (DCB) for treating PAD is mainly attributable to the availability of good clinical data demonstrating the efficacy and safety of DCB technology. Since the bulk of DCB devices is commercially available for PAD indication, this sector accounts for the most significant share. The market is further expanding due to factors such as the rapid growth of the aging population, the consequent rise in the prevalence of peripheral artery illnesses, and an increase in product approvals. The growth of peripheral artery disease is also fueled by an increase in diabetes patients.

By drug type, the market is divided into paclitaxel and sirolimus. Given that these products are secure and efficient in treating urological, aortic valve (AV), and cardiovascular (CVD) problems, the paclitaxel market sector holds the largest portion of the overall market. In the PCI technique, particularly for CVDs, the paclitaxel-coated balloon (PCB) technology has emerged as a viable therapeutic alternative. The vast majority of DCBs that are marketed are paclitaxel-coated. Clinical evidence suggests that paclitaxel-coated balloons lower the risk of restenosis following angioplasty of atherosclerotic femoropopliteal lesions. Their demand among healthcare professionals is rising as a result.

By end-user, the market is divided into hospitals, ambulatory care settings, and freestanding cath labs. In 2021, the hospital segment owned the largest market share. Surgeons choose the increasingly used drug-coating balloon catheters as a reliable technique for administering medication during surgical procedures. Furthermore, patients are choosing hospitals and clinics more frequently due to the improved post-surgical care offered by the caregivers and nursing staff.

Recent Developments

• In February 2021, L2Mtech GmbH received its first CE mark on six products. This confirms the effectiveness and safety of the company's cutting-edge cardiovascular and endovascular applications and represents a turning point in its history. The business intends to introduce products that bear the CE mark commercially.

Drug-Coated Balloons Market: Report Scope

Drug-Coated Balloons Market: Regional Landscape

North America dominated the global drug-coated balloons market in 2021

The market for drug-coated balloons was dominated by the North American area in 2021. The high prevalence of cardiovascular disease diagnosis and treatment, along with rising healthcare spending, is expected to bode well for the drug-coated balloon industry in North America. Additionally, it is anticipated that advantageous reimbursement rules and increased product innovation will fuel sales growth in the local market. The largest market for drug-coated balloons in North America is the United States, followed by Canada. With the rising rates of obesity, unhealthy lifestyle choices, an aging population, the presence of influential figures, and high spending potential, the region has been experiencing an increase in cardiac problems. As a result, drug-coated balloon catheter (DCB) sales are increasing, especially in the United States.

Drug-Coated Balloons Market: Competitive Landscape 

Some of the main competitors dominating the global drug-coated balloons market include -

• Aachen Resonance
• Acotec Scientific
• AR Baltic Medical
• Biosensors International Group
• BIOTRONIK
• Cardionovum
• Concept Medical
• Eucatech
• ENDOCOR
• HEXACATH
• iVascular
• MA Med Alliance
• Meril Life Sciences
• Nano Therapeutics
• QT Vascular
• RD Global-Invamed
• STENTYS, Surmodics
• Terumo, Urotronic
• Welling.

Global Drug-Coated Balloons Market is segmented as follows:

By Indication

• PAD
• CAD
• Others

By Drug Type

• Paclitaxel
• Sirolimus

By End-user

• Hospitals
• Ambulatory Care Settings
• Freestanding Cath Labs

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa